[Ticlid--a new development in the treatment and prevention of arterial thromboses].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to I N Bokarev.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
273 patients suffering from ischemic heart disease were treated with Anturan for one year at a daily dosage of 800 mg. The number of cardiovascular complications was significantly reduced, compared to the control group.
Clinical course of the disease and the formation of the necrotic focus (as evidenced by precordial mapping from 35 ECG leads) were assessed in 88 patients with acute myocardial infarction, treated with 1,000,000 IU urokinase, in comparison to 41 untreated control patients. Thrombolytic therapy, started within the first 6 hours of myocardial infarction, was associated with a better clinical course of the disease. Urokinase administration after 6 hours from the onset of the symptoms produced no clinical improvement, did not limit the necrotic focus and failed to reduce mortality, as compared to the controls. The assessment of the efficiency of thrombolytic treatment demonstrated an at least 30% increment of venous flow in 45% of patients. Intravenous urokinase administration was accompanied by an activation of blood fibrinolytic system, and there was a tendency to fibrinolysis depression on the day following the administration.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
A new thrombolytic drug, renokinase, was administered intravenously to 30 patients with macrofocal myocardial infarction (MI), admitted to hospital within early hours of its onset. Changes in the venous network of the heart were assessed, using continuous thermodilution, in the presence of thrombolytic treatment. Coronary venous flow was shown to increase by 20% and more in 17 patients, more than 30% in 15 patients, and more than 40% in 10. Low MI was associated with a significant increase of blood flow rate in the coronary sinus as well as other cardiac veins, while anterior MI was associated with flow rate increase in the coronary sinus only. A 20-30% increase in any of the coronary flow parameters limited the necrosis focus, as evidenced by precordial mapping from 35 ECG leads. Renokinase (60,000 units) was well tolerated by the patients.